Impacts of HER2-overexpression and molecular targeting therapy on the efficacy of stereotactic radiosurgery for brain me
- PDF / 312,782 Bytes
- 9 Pages / 595.276 x 790.866 pts Page_size
- 22 Downloads / 128 Views
CLINICAL STUDY
Impacts of HER2-overexpression and molecular targeting therapy on the efficacy of stereotactic radiosurgery for brain metastases from breast cancer Shoji Yomo • Motohiro Hayashi • Narisumi Cho
Received: 13 August 2012 / Accepted: 1 January 2013 / Published online: 8 January 2013 Ó Springer Science+Business Media New York 2013
Abstract Advances in chemotherapy for breast cancer (BC) have prolonged overall survival, especially for patients with human epidermal growth factor receptor-2 (HER2) positive cancer. We evaluated the effectiveness and limitations of stereotactic radiosurgery (SRS) for brain metastases (BM) from BC in conjunction with molecular targeting chemotherapy. Outcomes were retrospectively reviewed in 80 consecutive patients who underwent gamma knife SRS for BM from BC between January 2009 and February 2012. The overall survival (OS), neurological death-free survival (NS) and local tumor control endpoints were calculated, and prognostic factors were investigated using proportional hazards models. In 40 patients with HER2-overexpression, treatment results were compared between two sub-groups: lapatinib-based therapy (24 patients) versus non-lapatinibbased therapy (16 patients). The rates of 1- and 2-year OS after SRS were 50 and 26 %, respectively. The median survival time (MST) was 11.4 months. HER2-overexpression (P \ 0.001), recursive partitioning analysis class (P = 0.018) and total planning target volume on initial SRS (P = 0.004) were associated with OS. The MSTs in HER2positive and –negative patients were 16.6 and 7.1 months, respectively (P = 0.001). The rates of 1- and 2-year NS were 90 and 78 %, respectively. The rates of 1- and 2-year local tumor control were 84 and 70 %, respectively. Factors associated with local tumor control included lesion volume (P \ 0.001) and peripheral dose (P = 0.003). In sub-analysis of patients with HER2-overexpression, lapatinib-based chemotherapy was also associated with better local tumor control (P = 0.002). The 1-year local tumor control rate of S. Yomo (&) M. Hayashi N. Cho Saitama Gamma Knife Center, San-ai Hospital, 4-35-17, Tajima, Sakura-ku, Saitama 338-0837, Japan e-mail: [email protected]
the lapatinib group was significantly better than that of the non-lapatinib group (86 vs. 69 %, P \ 0.001). SRS is a safe and effective management option for selected patients with BM from BC. Patients with HER2-overexpressing tumors were found to be a distinct subgroup for which a longer survival time can be expected. Synergistic anti-tumor effects of lapatinib on BM in conjunction with SRS were suggested. Keywords Breast cancer Brain metastases Stereotactic radiosurgery HER2-overexpression Lapatinib
Introduction Brain metastases (BM) are a significant cause of morbidity and death for cancer patients. Breast cancer (BC) is second only to lung cancer as a source of metastatic brain tumors [1]. As a consequence of improvements in diagnostic and therapeutic options and a corresponding improvement in survival, BM are now more frequently di
Data Loading...
